美国成人灭活脊髓灰质炎疫苗使用:免疫实践咨询委员会更新建议——美国,2023年
2022年纽约一名未接种疫苗的年轻成人发生由疫苗衍生2型脊髓灰质炎病毒引起的麻痹性脊髓灰质炎,凸显美国输入和传播风险。2023年6月21日,免疫实践咨询委员会(ACIP)投票建议所有已知或怀疑未接种或未全程接种脊髓灰质炎疫苗的≥18岁美国成人,使用灭活脊髓灰质炎疫苗(IPV)完成基础免疫系列。本报告总结该建议的证据并给出成人IPV使用临床指导。
要点
- 2022年纽约一未接种疫苗年轻成人发生疫苗衍生2型脊髓灰质炎病毒所致麻痹性脊髓灰质炎。
- ACIP建议已知或怀疑未接种或未全程接种的≥18岁美国成人完成IPV基础免疫系列。
- 本报告总结证据并给出成人IPV使用临床指导。
核心结论
- ACIP建议所有已知或怀疑未接种或未全程接种脊髓灰质炎疫苗的≥18岁美国成人,使用IPV完成基础免疫系列。
研究设计与样本
- 2022年10月至2023年6月,ACIP脊髓灰质炎疫苗工作组审查了脊髓灰质炎病毒监测与流行病学、IPV安全性和有效性等数据,并依据ACIP证据到推荐框架进行审议。
- 2023年6月21日,ACIP投票通过上述建议。
主要发现
- 尽管2型和3型野生脊髓灰质炎病毒已消灭,1型野生脊髓灰质炎病毒和疫苗衍生脊髓灰质炎病毒仍在全球多国循环。
- 2022年纽约一名未接种疫苗的年轻成人被确定为疫苗衍生2型脊髓灰质炎病毒引起的麻痹性脊髓灰质炎病例,后续检测到社区传播。
- 该病例和社区传播凸显脊髓灰质炎病毒输入美国以及未接种者发生脊髓灰质炎的风险。
- 此前ACIP成人脊髓灰质炎疫苗接种建议仅限于已知暴露风险增加的成人。
临床怎么用
- 所有已知或怀疑未接种或未全程接种脊髓灰质炎疫苗的≥18岁美国成人,应使用IPV完成基础免疫系列。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Poliovirus can cause poliomyelitis and lifelong paralysis. Although wild poliovirus types 2 and 3 have been eradicated, wild poliovirus type 1 and vaccine-derived polioviruses are still circulating in multiple countries worldwide. In 2022, a case of paralytic polio caused by vaccine-derived poliovirus type 2 was identified in an unvaccinated young adult in New York. This case and subsequent detection of community transmission underscored the ongoing risk for importation of poliovirus into the United States and risk for poliomyelitis among unvaccinated persons. However, previous Advisory Committee on Immunization Practices (ACIP) recommendations for adult polio vaccination were limited to adults known to be at increased risk for exposure. During October 2022-June 2023, the ACIP Polio Vaccine Work Group reviewed data on poliovirus surveillance and epidemiology, safety and effectiveness of inactivated poliovirus vaccine (IPV), and other considerations outlined in the ACIP Evidence to Recommendations Framework. On June 21, 2023, ACIP voted to recommend that all U.S. adults aged ≥18 years who are known or suspected to be unvaccinated or incompletely vaccinated against polio complete a primary polio vaccination series with IPV. This report summarizes evidence considered for this recommendation and provides clinical guidance for the use of IPV in adults.
引用
- Kidd S, Clark T, Routh J, et al. Use of Inactivated Polio Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023. PMID: 38060431. doi:10.15585/mmwr.mm7249a3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。